A research team co-led by scientists at the University of Arizona College of Medicine—Tucson found that an osteoporosis drug ...

Metabolic dysfunction-associated steatohepatitis (MASH) significantly increases the risk of liver cirrhosis and ...

Sotagliflozin, a drug recently approved by the Food and Drug Administration to treat type 2 diabetes and kidney disease with additional cardiovascular risk factors, can significantly reduce heart ...

Oral vancomycin therapy resulted in clinical response in nearly half of patients with inflammatory bowel disease associated ...

Patients with psoriasis, psoriatic arthritis, and axial spondylarthritis using ixekizumab have a low incidence rate of cerebro-cardiovascular events.